Jonathan Aschoff
Stock Analyst at Roth MKM
(0.51)
# 3,948
Out of 4,876 analysts
43
Total ratings
25%
Success rate
-35.97%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GTBP GT Biopharma | Initiates: Buy | $11 | $3.45 | +218.84% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $9.07 | +131.53% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $11,100 → $5,920 | $3.16 | +187,241.77% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.66 | +984.34% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $17 | $0.23 | +7,211.83% | 2 | Aug 13, 2024 | |
| OTRK Ontrak | Maintains: Buy | $60 → $45 | $0.53 | +8,390.57% | 2 | Aug 9, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $20 | $0.94 | +2,024.50% | 1 | Jul 16, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Maintains: Buy | $336 → $176 | $0.33 | +52,468.70% | 2 | May 3, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $40 | $0.32 | +12,439.18% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $20 → $28 | $7.89 | +254.88% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $36 | $6.71 | +436.51% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $360 | $0.23 | +157,518.21% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $5.85 | +412.82% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $3.77 | +5,204.90% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $2.24 | +525.00% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2,400 → $7,200 | $0.79 | +916,396.95% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $1.02 | +684.31% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $2.75 | +3,536.36% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.60 | +66,511.16% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $4.81 | +690.84% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $360,000 | $4.90 | +7,346,838.78% | 1 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $2.20 | +4,273.58% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $5.43 | +139.63% | 1 | Dec 19, 2019 |
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $3.45
Upside: +218.84%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $9.07
Upside: +131.53%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $11,100 → $5,920
Current: $3.16
Upside: +187,241.77%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.66
Upside: +984.34%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $17
Current: $0.23
Upside: +7,211.83%
Ontrak
Aug 9, 2024
Maintains: Buy
Price Target: $60 → $45
Current: $0.53
Upside: +8,390.57%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $0.94
Upside: +2,024.50%
Cyclacel Pharmaceuticals
May 3, 2024
Maintains: Buy
Price Target: $336 → $176
Current: $0.33
Upside: +52,468.70%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $0.32
Upside: +12,439.18%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $20 → $28
Current: $7.89
Upside: +254.88%
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $6.71
Upside: +436.51%
Mar 5, 2024
Maintains: Buy
Price Target: $75 → $360
Current: $0.23
Upside: +157,518.21%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $5.85
Upside: +412.82%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $3.77
Upside: +5,204.90%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $2.24
Upside: +525.00%
Feb 14, 2023
Maintains: Buy
Price Target: $2,400 → $7,200
Current: $0.79
Upside: +916,396.95%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $1.02
Upside: +684.31%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $2.75
Upside: +3,536.36%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.60
Upside: +66,511.16%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $4.81
Upside: +690.84%
Feb 12, 2021
Initiates: Buy
Price Target: $360,000
Current: $4.90
Upside: +7,346,838.78%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $2.20
Upside: +4,273.58%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $5.43
Upside: +139.63%